AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29502350 — intervention group
Group type: COMPARATOR
Intervention: Postmeal protein-enriched, dietary fiber-fortified bar (PFB)
Number of subjects: 30
Study 28699295 — intervention group
Group type: EXPERIMENTAL
Intervention: Peyton's four-step approach
Number of subjects: 39
Study 28699295 — intervention group
Group type: COMPARATOR
Intervention: See one, do one approach
Number of subjects: 39
Study 25434773 — intervention group
Group type: COMPARATOR
Intervention: AP-DSD measurements
Number of subjects: 96
Study 25434773 — intervention group
Group type: COMPARATOR
Intervention: TR-DSD measurements
Number of subjects: 96
Study 25434773 — intervention group
Group type: EXPERIMENTAL
Intervention: AP-DSD and TR-DSD in Marfan patients
Number of subjects: 96
Study 25434773 — intervention group
Group type: COMPARATOR
Intervention: DSR (DSD/VBD) in males
Number of subjects: 96
Study 25434773 — intervention group
Group type: COMPARATOR
Intervention: AP-DSD and TR-DSD for discrimination
Number of subjects: 96
Study 22616770 — intervention group
Group type: EXPERIMENTAL
Intervention: ThinPrep® Imaging System (TIS)
Number of subjects: 169917
Study 22616770 — intervention group
Group type: COMPARATOR
Intervention: Manual screening (Control)
Number of subjects: 169917
Study 21984028 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 1 μg/kg IV
Number of subjects: 84
Study 21984028 — intervention group
Group type: COMPARATOR
Intervention: N/S 0.9% (placebo)
Number of subjects: 84
Study 18287439 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced sonography
Number of subjects: 116
Study 18287439 — intervention group
Group type: COMPARATOR
Intervention: Baseline sonography
Number of subjects: 116
Study 16921047 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus cisplatin (GemCis arm)
Number of subjects: 195
Study 16921047 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine alone (Gem arm)
Number of subjects: 195
Study 12665684 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid-menadione
Number of subjects: 0
Study 11024374 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent aortic cross-clamping (IAC)
Number of subjects: 103
Study 11024374 — intervention group
Group type: COMPARATOR
Intervention: Cardioplegic arrest (CA)
Number of subjects: 103
Study 8784217 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG) as add-on therapy
Number of subjects: 0
Study 8784217 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG)
Number of subjects: 0
Study 2085059 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg vitamin E (d‐alpha‐tocopherolacetate, V, n = 26)
Number of subjects: 53
Study 2085059 — intervention group
Group type: COMPARATOR
Intervention: 50 mg Diclofenac (D, n = 27)
Number of subjects: 53
Study 2085059 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg vitamin E (V)
Number of subjects: 53
Study 2085059 — intervention group
Group type: COMPARATOR
Intervention: 50 mg Diclofenac (D)
Number of subjects: 53
Study 2085059 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 53
Study 492827 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric telephone protocols administered by health assistants
Number of subjects: 0
Study 492827 — intervention group
Group type: COMPARATOR
Intervention: Current system in the emergency room
Number of subjects: 0
Study 492827 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric telephone protocols
Number of subjects: 0
Study 30980079 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully robotic Ivor Lewis esophageal resection (RAMIE4)
Number of subjects: 100
Study 29089196 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized functional wrist orthosis (n = 15)
Number of subjects: 30
Study 29089196 — intervention group
Group type: COMPARATOR
Intervention: No orthotic (control group, n = 15)
Number of subjects: 30
Study 28476313 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable mesh
Number of subjects: 8
Study 28476313 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium mesh
Number of subjects: 8
Study 25818032 — intervention group
Group type: EXPERIMENTAL
Intervention: Instillation of 5 ml 2% lidocaine gel in the urethra 5 minutes before catheterization
Number of subjects: 94
Study 25818032 — intervention group
Group type: COMPARATOR
Intervention: Lubrication of the distal part of the catheter with 5 ml 2% lidocaine gel
Number of subjects: 94
Study 22970751 — intervention group
Group type: EXPERIMENTAL
Intervention: Single miniscrews (group A, n = 12)
Number of subjects: 25
Study 22970751 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual miniscrews (group B, n = 13)
Number of subjects: 25
Study 21710870 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential oil-containing mouth rinse (Cool Mint Listerine Antiseptic)
Number of subjects: 36
Study 21710870 — intervention group
Group type: COMPARATOR
Intervention: Negative control rinse
Number of subjects: 36
Study 19853691 — intervention group
Group type: EXPERIMENTAL
Intervention: Trials reporting race/ethnicity information
Number of subjects: 156
Study 19853691 — intervention group
Group type: EXPERIMENTAL
Intervention: NIH-funded trials
Number of subjects: 156
Study 17095338 — intervention group
Group type: EXPERIMENTAL
Intervention: ALTU‐135 (5000 units of lipase)
Number of subjects: 117
Study 17095338 — intervention group
Group type: EXPERIMENTAL
Intervention: ALTU‐135 (25000 units of lipase)
Number of subjects: 117
Study 17095338 — intervention group
Group type: EXPERIMENTAL
Intervention: ALTU‐135 (100000 units of lipase)
Number of subjects: 117
Study 14973217 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-cm margin of excision
Number of subjects: 900
Study 14973217 — intervention group
Group type: COMPARATOR
Intervention: 3-cm margin of excision
Number of subjects: 900
Study 11207991 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin infusion (1 g/kg bodyweight, i.v., during the first 2 h of phototherapy)
Number of subjects: 58
Study 11207991 — intervention group
Group type: COMPARATOR
Intervention: Control group (only phototherapy)
Number of subjects: 58
Study 9275035 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF (Cyclophosphamide, Methotrexate, and Fluorouracil)
Number of subjects: 589
Study 9275035 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC (Fluorouracil, 4' Epirubicin, Cyclophosphamide)
Number of subjects: 589
Study 9275035 — intervention group
Group type: EXPERIMENTAL
Intervention: FECMP (Fluorouracil, 4' Epirubicin, Cyclophosphamide, Methotrexate, Prednisone)
Number of subjects: 589
Study 9275035 — intervention group
Group type: COMPARATOR
Intervention: CMF/EC
Number of subjects: 589
Study 7912393 — intervention group
Group type: EXPERIMENTAL
Intervention: Molsidomine (1 mg/h intravenously for 48 h, followed by 16 mg molsidomine by mouth daily for 12 days)
Number of subjects: 4017
Study 7912393 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical to molsidomine treatment)
Number of subjects: 4017
Study 7912393 — intervention group
Group type: EXPERIMENTAL
Intervention: Molsidomine
Number of subjects: 4017
Study 7912393 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4017
Study 3142511 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine 120 mg
Number of subjects: 10
Study 3142511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31866092 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage Radiation Therapy (SRT) ± Salvage Hormone Therapy (SHT) (64.8 Gy of SRT followed by 80 mg bicalutamide and LHRH agonist if BCL fails)
Number of subjects: 210
Study 31866092 — intervention group
Group type: COMPARATOR
Intervention: Salvage Hormone Therapy (SHT) (80 mg bicalutamide followed by LHRH agonist in case of BCL failure)
Number of subjects: 210
Study 31866092 — intervention group
Group type: EXPERIMENTAL
Intervention: SRT ± SHT
Number of subjects: 210
Study 31866092 — intervention group
Group type: COMPARATOR
Intervention: SHT
Number of subjects: 210
Study 30797825 — intervention group
Group type: EXPERIMENTAL
Intervention: STEEP (incremental step heights)
Number of subjects: 45
Study 30797825 — intervention group
Group type: COMPARATOR
Intervention: CONTROL (non-training)
Number of subjects: 45
Study 29116013 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (40 mg intravenous injection)
Number of subjects: 38
Study 29116013 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dexamethasone)
Number of subjects: 38
Study 25550188 — intervention group
Group type: EXPERIMENTAL
Intervention: Red orange juice
Number of subjects: 18
Study 25550188 — intervention group
Group type: EXPERIMENTAL
Intervention: Blond orange juice
Number of subjects: 18
Study 25550188 — intervention group
Group type: COMPARATOR
Intervention: Water (Control)
Number of subjects: 18
Study 24180149 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone prophylactically at induction (group B)
Number of subjects: 100
Study 24180149 — intervention group
Group type: COMPARATOR
Intervention: Placebo at induction (group A)
Number of subjects: 100
Study 24180149 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 100
Study 21449786 — intervention group
Group type: COMPARATOR
Intervention: Double placebo (placebo injection plus childhood oral placebo)
Number of subjects: 149
Study 21449786 — intervention group
Group type: COMPARATOR
Intervention: Estrogen alone (placebo injection plus childhood oral low-dose estrogen)
Number of subjects: 149
Study 21449786 — intervention group
Group type: COMPARATOR
Intervention: Growth hormone alone (growth hormone injection plus childhood oral placebo)
Number of subjects: 149
Study 21449786 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone-estrogen (growth hormone injection plus childhood oral low-dose estrogen)
Number of subjects: 149
Study 21449786 — intervention group
Group type: COMPARATOR
Intervention: Growth hormone treatment (vs. placebo)
Number of subjects: 149
Study 21449786 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone-estrogen vs. growth hormone alone
Number of subjects: 149
Study 19692688 — intervention group
Group type: COMPARATOR
Intervention: Letrozole monotherapy
Number of subjects: 6182
Study 19692688 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen followed by Letrozole
Number of subjects: 6182
Study 19692688 — intervention group
Group type: COMPARATOR
Intervention: Letrozole followed by Tamoxifen
Number of subjects: 6182
Study 16388875 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ‐5D
Number of subjects: 285
Study 16388875 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Analogue Scale (VAS)
Number of subjects: 285
Study 12560406 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (5 g/d + 2 g of dextrose)
Number of subjects: 28
Study 12560406 — intervention group
Group type: COMPARATOR
Intervention: Placebo (7 g of dextrose)
Number of subjects: 28
Study 11192131 — intervention group
Group type: EXPERIMENTAL
Intervention: Amprenavir (APV) in combination with 2 nucleoside reverse transcriptase inhibitors
Number of subjects: 626
Study 11192131 — intervention group
Group type: EXPERIMENTAL
Intervention: Amprenavir (APV)
Number of subjects: 626
Study 9098860 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuberculin skin test (TST) with > 1.5 cm2 reaction during acute phase
Number of subjects: 11
Study 9098860 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate strength PPD inoculation (5 TU)
Number of subjects: 11
Study 9098860 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation with 0.05 TU/mL of PPD
Number of subjects: 11
Study 9098860 — intervention group
Group type: COMPARATOR
Intervention: Control T cells
Number of subjects: 11
Study 8233534 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg diclofenac
Number of subjects: 10
Study 8233534 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 10
Study 3912335 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide 200 mg suppositories
Number of subjects: 81
Study 3912335 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 100 mg suppositories
Number of subjects: 81
Study 3912335 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 29979742 — intervention group
Group type: COMPARATOR
Intervention: $0 incentive
Number of subjects: 8715
Study 29979742 — intervention group
Group type: EXPERIMENTAL
Intervention: $1 incentive
Number of subjects: 8715
Study 29979742 — intervention group
Group type: EXPERIMENTAL
Intervention: $5 incentive
Number of subjects: 8715
Study 29979742 — intervention group
Group type: EXPERIMENTAL
Intervention: $10 incentive
Number of subjects: 8715
Study 29979742 — intervention group
Group type: EXPERIMENTAL
Intervention: Active-choice testing
Number of subjects: 8715
Study 29979742 — intervention group
Group type: EXPERIMENTAL
Intervention: Opt-out testing
Number of subjects: 8715
Study 27486293 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth extraction video
Number of subjects: 64
Study 27486293 — intervention group
Group type: COMPARATOR
Intervention: Verbal information and routine warnings
Number of subjects: 64
Study 23982988 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week exercise therapy
Number of subjects: 95
Study 21354934 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg/kg pentazocine with 1.5 mg/kg propofol
Number of subjects: 81
Study 21354934 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mg/kg pentazocine with 1.5 mg/kg propofol
Number of subjects: 81
Study 18720001 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 3 mg daily for 30 days
Number of subjects: 34
Study 18720001 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 3 mg daily for 8 weeks
Number of subjects: 34
Study 18720001 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 17110021 — intervention group
Group type: EXPERIMENTAL
Intervention: TVT
Number of subjects: 72
Study 17110021 — intervention group
Group type: EXPERIMENTAL
Intervention: TVT-O
Number of subjects: 72
Study 15008868 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA applied on both anterior and posterior surfaces of the ear (Group A)
Number of subjects: 22
Study 15008868 — intervention group
Group type: COMPARATOR
Intervention: EMLA applied on only one side of the ear (Group B)
Number of subjects: 22
Study 11281500 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 50-200 mg/day
Number of subjects: 82
Study 9393427 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular implants
Number of subjects: 2212
Study 9393427 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxillary implants
Number of subjects: 2212
Study 9393427 — intervention group
Group type: EXPERIMENTAL
Intervention: Implants in bone quality 1
Number of subjects: 2212
Study 9393427 — intervention group
Group type: EXPERIMENTAL
Intervention: Implants in bone quality 2
Number of subjects: 2212
Study 9393427 — intervention group
Group type: EXPERIMENTAL
Intervention: Implants in bone quality 3
Number of subjects: 2212
Study 9393427 — intervention group
Group type: EXPERIMENTAL
Intervention: Implants in bone quality 4
Number of subjects: 2212
Study 7683190 — intervention group
Group type: EXPERIMENTAL
Intervention: High lipase preparation
Number of subjects: 18
Study 3116770 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate purity factor VIII concentrate (not heat-treated)
Number of subjects: 46
Study 3116770 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-treated concentrates of higher purity
Number of subjects: 46
Study 3116770 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-treated concentrates of lower purity
Number of subjects: 46
Study 3116770 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate purity factor VIII concentrate (heat-treated)
Number of subjects: 46
Study 282003 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous administration of cytosine arabinoside (Ara-C) 150 mg/m2 and methotrexate (MTX) 40 mg/m2
Number of subjects: 56
Study 282003 — intervention group
Group type: COMPARATOR
Intervention: Sequential administration of cytosine arabinoside (Ara-C) 150 mg/m2 and methotrexate (MTX) 40 mg/m2
Number of subjects: 56
Study 31994007 — intervention group
Group type: EXPERIMENTAL
Intervention: PEGASUS intervention, a standardised two-stage process for shared decision-making.
Number of subjects: 180
Study 31994007 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 180
Study 30261340 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-use adsorptive media water filtration device for arsenic removal
Number of subjects: 371
Study 30261340 — intervention group
Group type: COMPARATOR
Intervention: Community water arsenic testing program
Number of subjects: 371
Study 30261340 — intervention group
Group type: COMPARATOR
Intervention: Low-range field rapid arsenic testing kit
Number of subjects: 371
Study 28243855 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS-based propofol dosing
Number of subjects: 60
Study 28243855 — intervention group
Group type: COMPARATOR
Intervention: LBW-based propofol dosing
Number of subjects: 60
Study 28243855 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS-based and LBW-based propofol dosing
Number of subjects: 60
Study 25844841 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose infliximab (3.5 mg/kg)
Number of subjects: 123
Study 25844841 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose infliximab (5 mg/kg)
Number of subjects: 123
Study 25844841 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study 23820795 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO) therapy
Number of subjects: 50
Study 23820795 — intervention group
Group type: COMPARATOR
Intervention: Intratympanic (IT) steroid injection
Number of subjects: 50
Study 21383391 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative electroacupuncture (EA) for 30 min at bilateral points (LI4‐LI11, LR3‐ST36, PC6‐TE5) with alternating frequencies of 3 and 15 Hz
Number of subjects: 22
Study 21383391 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative electroacupuncture (EA)
Number of subjects: 22
Study 21383391 — intervention group
Group type: COMPARATOR
Intervention: Sham transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 22
Study 19549185 — intervention group
Group type: EXPERIMENTAL
Intervention: Short pulse (SP) VSP Er:YAG laser resurfacing
Number of subjects: 24
Study 19549185 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra-long pulse (XLP) VSP Er:YAG laser resurfacing
Number of subjects: 24
Study 17159456 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (8 weeks treatment)
Number of subjects: 32
Study 15233773 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive software application
Number of subjects: 52
Study 15233773 — intervention group
Group type: COMPARATOR
Intervention: Static web page (Control)
Number of subjects: 52
Study 11487379 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril
Number of subjects: 40
Study 11487379 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 40
Study 11487379 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study 9763328 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing and oral hygiene combined with local controlled drug delivery with tetracycline fibers
Number of subjects: 127
Study 9763328 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing with oral hygiene instructions
Number of subjects: 127
Study 7875182 — intervention group
Group type: EXPERIMENTAL
Intervention: meperidine 2 mg.kg‐1 (M)
Number of subjects: 40
Study 7875182 — intervention group
Group type: EXPERIMENTAL
Intervention: meperidine 2 mg.kg‐1 plus midazolam 0.05 mg.kg‐1 (M + M)
Number of subjects: 40
Study 3213917 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 50
Study 3213917 — intervention group
Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 50
Study 29866205 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 300
Study 29866205 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 28012181 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% trichloroacetic acid (TCA)
Number of subjects: 28
Study 28012181 — intervention group
Group type: COMPARATOR
Intervention: 5-aminolaevulinic acid (ALA) photodynamic therapy (PDT)
Number of subjects: 28
Study 26851256 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyber Friendly Schools Project intervention
Number of subjects: 3382
Study 26851256 — intervention group
Group type: EXPERIMENTAL
Intervention: Forms of Bullying Scale (FBS)
Number of subjects: 3382
Study 23233342 — intervention group
Group type: EXPERIMENTAL
Intervention: Heroin-assisted treatment
Number of subjects: 156
Study 21820084 — intervention group
Group type: EXPERIMENTAL
Intervention: JTE-607 (0.1 mg/kg/h)
Number of subjects: 9
Study 21820084 — intervention group
Group type: EXPERIMENTAL
Intervention: JTE-607 (0.3 mg/kg/h)
Number of subjects: 9
Study 21820084 — intervention group
Group type: EXPERIMENTAL
Intervention: JTE-607 (0.03 mg/kg/h)
Number of subjects: 9
Study 18075221 — intervention group
Group type: EXPERIMENTAL
Intervention: Dressing containing 800 mg of plant sterol (PS), 15 g daily for 12 weeks
Number of subjects: 59
Study 18075221 — intervention group
Group type: COMPARATOR
Intervention: Placebo dressing without PS
Number of subjects: 59
Study 17076934 — intervention group
Group type: EXPERIMENTAL
Intervention: tiapride (300 mg/d)
Number of subjects: 299
Study 17076934 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 299
Study 15049438 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosulpiride preparation 1 (25 mg)
Number of subjects: 28
Study 15049438 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosulpiride preparation 2 (25 mg)
Number of subjects: 28
Study 11472859 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS in the left dorsolateral prefrontal cortex
Number of subjects: 8
Study 11472859 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 8
Study 9150779 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium 100 micrograms/kg
Number of subjects: 75
Study 9150779 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 1200 micrograms/kg
Number of subjects: 75
Study 9150779 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium 140 micrograms/kg
Number of subjects: 75
Study 9150779 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 600 micrograms/kg
Number of subjects: 75
Study 9150779 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 900 micrograms/kg
Number of subjects: 75